Why Attend the 5th Precision Medicine in IBD Summit?
Getting the Right Drug, to the Right IBD Patient, at the Right Time.
In its 5th year, the Precision Medicine in Inflammatory Bowel Disease Summit will continue bringing IBD experts together to advance precision medicine approaches and to tackle the persistently low response rates and challenging efficacy ceilings. Across three focused days, expect practical insights on navigating combination approaches, uncovering novel biomarkers, validating AI-driven drug discovery and data analysis, and exploring next generation IBD therapies.
Through real-world case studies, peer-led discussions, and interactive sessions, learn how organizations are advancing biomarker development, optimizing translational approaches, and innovating trial design to adopt a precision medicine strategy and leave behind ‘trial and error’ treatment. Come to hear data-driven insights, and leave with a community of like-minded peers, dedicated to advancing precision medicine for IBD patients who need truly personalized care.
What's New for 2027?
Return of the Technology Focus Day
Roche demonstrates how AI-enhanced digital pathology can identify relevant IBD endotypes, and AbbVie combines single-cell with spatial omics to better understand disease heterogeneity and gain meaningful data-driven insights.
8+ New Biopharma Companies Presenting
Our returning speakers from J&J, Takeda, AbbVie, Merck and Xencor, will be joined by the fresh perspectives and insights from leading experts such as Roche, AltruBio, Mirador Therapeutics and more to hear from all areas of the IBD drug development landscape.
Brand New Mini-Workshop Format
Be the first to take part in our combination therapy mini-workshop with leaders from Merck, Takeda and J&J to address complementary MOAs and weigh up potential off-target effects. In this hypothetical therapeutic match-making experience, you will form new ideas and partnership opportunities to advance the IBD field through collaboration.
Combination Therapy Spotlight
With a renewed excitement around the potential of combination therapies for breaking the efficacy ceiling from IBD, AbbVie, Xencor and Coultreon BioPharma discuss optimal pathway targeting, TL1a/IL-23 blockade, and patient stratification strategies to maximize efficacy and reduce off-target effects.
Exploring Novel Therapies
This year welcomes novel therapeutics including at fecal microbiota transplant, IL-23 and TL1a targeting and cell depletion approaches. Learn from Metagen Therapeutics, OSE Immunotherapeutics, and Arda Therapeutics to understand how they will transform the therapeutic landscape for IBD precision medicine.
Explore the 2027 Full Event Guide
- DISCOVER how biopharma is moving beyond ‘trial and error’ treatment approaches
- SHAPE your patient stratification strategies with predictive biomarker advances
- BUILD your understanding of the multi-omic, spatial-omics and AI-driven technologies
- LEARN how IBD is taking notes from oncology endpoints, to transform trial design
- CONNECT with 60+ leader of the Precision Medicine community across IBD drug development
Attending Companies Include
Explore the Agenda
Discover exactly how leading teams are tackling challenges from combination therapies to AI-driven biomarker discovery, to see how your program can benefit.
Partner With Us
Position your solutions in front of decision-makers actively looking for support with their precision medicine approaches, and become a trusted partner worldwide.
Join IBD Leaders
Connect with the IBD community striving to stratify patients, through predictive biomarkers and better understanding of disease mechanism.